Skip to content

capsule

DRUG15 trials

Sponsors

Nanfang Hospital, Southern Medical University, Morphic Therapeutic Inc., Kartos Therapeutics Inc., Mirum Pharmaceuticals Inc., Acerta Pharma B.V.

Conditions

Advanced or Recurrent Endometrial CancerFungal infectionGastric diseasesMantle Cell LymphomaMetastatic Castration-Resistant Prostate CancerMetastatic Medullary Thyroid CancerModerately to Severely Active Crohn’s DiseaseModerately to severely active ulcerative colitis

Phase 1

Phase 2

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
Active, not recruitingCTIS2022-500953-17-00
Morphic Therapeutic Inc.Moderately to severely active ulcerative colitis
Start: 2023-03-23Target: 172Updated: 2025-12-11
A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Active, not recruitingCTIS2023-505764-11-00
Mirum Pharmaceuticals Inc.Pruritus associated with Primary Sclerosing Cholangitis (PSC)
Start: 2022-06-10Target: 105Updated: 2025-11-24
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
CompletedCTIS2022-502196-31-00
Kartos Therapeutics Inc.Advanced or Recurrent Endometrial Cancer
Start: 2023-08-21End: 2024-07-26Target: 140Updated: 2024-05-15
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 2 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET)
RecruitingCTIS2023-508158-24-00
Morphic Therapeutic Inc.Moderately to Severely Active Crohn’s Disease
Start: 2024-06-25Target: 150Updated: 2025-12-02
TSPO ligands in the treatment of depression: proof-of-concept of efficacy and underlying mechanisms of action
CompletedCTIS2024-512698-29-00
Medizinische Einrichtungen des Bezirks Oberpfalz KU AöRUnipolar/bipolar depressive disorder
Start: 2024-07-25End: 2025-11-21Target: 50Updated: 2025-06-26
The effect of amantadine as add-on therapy for motor fluctuations in advanced Parkinson’s disease: a randomized double-blinded placebo-controlled trial
RecruitingCTIS2023-509728-16-00
Centre Hospitalier Universitaire De Toulouseadvanced Parkinson’s disease
Start: 2025-10-10Target: 132Updated: 2026-01-23
A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR)
CompletedCTIS2024-517406-29-00
Sparrow Pharmaceuticals Inc.Polymyalgia rheumatica (PMR)
Start: 2022-07-26End: 2025-04-25Target: 72Updated: 2025-02-14

Phase 3

Phase 4

Unknown Phase

Related Papers